Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Change in Cash (2016 - 2025)

KalVista Pharmaceuticals' Change in Cash history spans 10 years, with the latest figure at -$35.7 million for Q2 2025.

  • For Q2 2025, Change in Cash fell 508.44% year-over-year to -$35.7 million; the TTM value through Apr 2025 reached -$17.1 million, up 29.88%, while the annual FY2025 figure was $100.5 million, 510.99% up from the prior year.
  • Change in Cash for Q2 2025 was -$35.7 million at KalVista Pharmaceuticals, down from $9.7 million in the prior quarter.
  • Across five years, Change in Cash topped out at $9.7 million in Q4 2024 and bottomed at -$35.7 million in Q2 2025.
  • The 3-year median for Change in Cash is $59000.0 (2024), against an average of -$7.2 million.
  • The largest annual shift saw Change in Cash soared 100.86% in 2024 before it tumbled 508.44% in 2025.
  • A 3-year view of Change in Cash shows it stood at $8.3 million in 2023, then rose by 17.88% to $9.7 million in 2024, then crashed by 466.47% to -$35.7 million in 2025.
  • Per Business Quant, the three most recent readings for KALV's Change in Cash are -$35.7 million (Q2 2025), $9.7 million (Q4 2024), and $59000.0 (Q3 2024).